Lyra Therapeutics, Inc.

NASDAQ
LYRA
paper.types.company
Rentabilité sur six mois: +2 078.95%
Rendement en dividendes: 0%
Secteur: Healthcare

4.14 $

+4.05 $ +4 615.26%
0.0849 $
4.14 $

paper.min_max_per_year

Calendrier des promotions Lyra Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

plus de détails
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2020-05-01
ISIN
US55234L1052
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 8.76 1
P/BV 1.16 9
P/E 0 0
Efficacité
Nom Signification Grade
ROA -89.43 0
ROE -184.99 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.5705 10
Debt/Ratio 0.5182 9
Debt/Equity 4.72 1
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 27.83 4
Rentabilité Ebitda, % 172.68 10
Rentabilité EPS, % -44.17 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.0878 $ 0 $ 0 $ 4615.26 % 0 % 0 %
common.calendar.number_days.7d 0.094 $ 0 $ 0 $ 4304.26 % 0 % 0 %
common.calendar.number_days.30d 0.0995 $ 0.0878 $ 4.14 $ 4060.8 % 0 % 0 %
common.calendar.number_days.90d 0.2052 $ 0.0849 $ 4.14 $ 1917.54 % 0 % 0 %
common.calendar.number_days.180d 0.19 $ 0.0849 $ 4.14 $ 2078.95 % 0 % 0 %
common.calendar.number_days.1y 0.3335 $ 0.0849 $ 4.14 $ 1141.38 % 0 % 0 %
common.calendar.number_days.3y 5.53 $ 0.0849 $ 6.6 $ -25.14 % 0 % 0 %
common.calendar.number_days.5y 18.56 $ 0.0849 $ 15.61 $ -77.69 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.0849 $ 18.56 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 0.1701 $ 0.0849 $ 4.14 $ 2333.86 % 0 % 0 %

Délit d'initié

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 année)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 années)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 années)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 année)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 année)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 années)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

Informations sur l'entreprise

Adresse: United States, Watertown. MA, 480 Arsenal Way - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://lyratherapeutics.com